Cargando…

547. Results of Patient-Reported Outcome Data From the Phase III BRIGHTE Study of Fostemsavir

BACKGROUND: The Phase 3 BRIGHTE study evaluated fostemsavir in heavily treatment experienced HIV-1 patients failing their current antiretroviral (ARV) regimen and unable to construct a viable regimen from remaining available agents. Week 24 efficacy and safety have been previously reported—fostemsav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Proudfoot, Clare, Ackerman, Peter, Llamoso, Cyril, Cella, David, Clark, Andrew, Murray, Miranda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255559/ http://dx.doi.org/10.1093/ofid/ofy210.555

Ejemplares similares

Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals
por: Anderson, Sarah-Jane, et al.
Publicado: (2021)

Pharmacokinetics of Temsavir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment
por: Sevinsky, Heather, et al.
Publicado: (2017)

Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure–Response Analysis
por: Lagishetty, Chakradhar, et al.
Publicado: (2020)

2500. Fostemsavir Drug–Drug Interaction Profile, an Attachment Inhibitor and Oral Prodrug of Temsavir, for Heavily Treatment Experienced HIV-1-Infected Patients
por: Moore, Katy P, et al.
Publicado: (2019)

Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense(®) Entry assay
por: Gartland, Margaret, et al.
Publicado: (2020)

Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid‐dependent, human immunodeficiency virus seronegative participants
por: Moore, Katy, et al.
Publicado: (2019)

834. Characterization of Heavily Treatment Experienced HIV-1 Infected Clinical Trial Participants Infected with SARS-CoV-2 COVID 19: Fostemsavir BRIGHTE Phase 3 Clinical Trial
por: Chabria, Shiven, et al.
Publicado: (2021)

Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
por: Gartland, Margaret, et al.
Publicado: (2022)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1
por: Ackerman, Peter, et al.
Publicado: (2021)

Fostemsavir for HIV-1 infection
Publicado: (2022)

1315. No Dose Adjustment of Metformin with Fostemsavir Coadministration Based on Mechanistic Static and Physiologically Based Pharmacokinetic Models
por: Nguyen, Dung N, et al.
Publicado: (2020)

547. Multidrug-Resistant Pseudomonas aeruginosa in an Academic Regional Burn Intensive Care Unit
por: Estelle, Carolee D, et al.
Publicado: (2019)

547. Molnupiravir and Nirmatrelvir/Ritonavir Effectiveness in Reducing the Risk for COVID-19 Disease Progression and Death
por: Paraskevis, Dimitrios, et al.
Publicado: (2023)

Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient
por: Bigirimana, Ferdinand, et al.
Publicado: (2023)

547. A Retrospective Cohort Study of Treatment Patterns and Clinical Outcomes in Patients with COVID-19
por: Pritchard, Haley, et al.
Publicado: (2020)

365. Durable efficacy and robust CD4+ T-cell count improvement observed across age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment
por: Dyson, Alftan, et al.
Publicado: (2023)

Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir
por: Wang, Tao, et al.
Publicado: (2021)

547 Neonatal outcomes of COVID-19 positive mothers
por: Zarudskaya, Oxana, et al.
Publicado: (2021)

547 Clinical Outcomes for Burned Patients with Covid-19
por: Walters, Elliot, et al.
Publicado: (2022)

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
por: Annunziata, Christina M., et al.
Publicado: (2012)

Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
por: Aberg, Judith A., et al.
Publicado: (2023)

Ovarian Tumours. A Ten Years' Record of 547 Cases
por: Green-Armytage, V. B.
Publicado: (1931)

Clinicopathological Review of 547 Bulbar Enucleations in Hungary (2006–2017)
por: Tóth, Gábor, et al.
Publicado: (2019)

547. Risk Factors Associated with 30-Day Mortality in a Large Cohort of Patients who Received Remdesivir and Corticosteroids for Severe COVID-19
por: Gupta, Kartik, et al.
Publicado: (2021)

SAT-547 Aldosterone-Potassium Ratio Predicts Primary Aldosteronism Subtype
por: Puar, Troy, et al.
Publicado: (2020)

Correction to Lancet Public Health 2021; 6: e547–56
Publicado: (2021)

THU547 Role Of NAD(+) Synthesis Pathway In PARP Inhibitor Resistance
por: Myong, Subin, et al.
Publicado: (2023)

The Bright Sides of Sadness in Late Life
por: Haase, Claudia, et al.
Publicado: (2020)

Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir
por: Lataillade, Max, et al.
Publicado: (2018)

Chloridæmia in Bright’s Disease
Publicado: (1907)

Pilocarpine in Bright’s Disease
Publicado: (1888)

547 An Earlier, More Severe Presentation of G6pc3 Deficiency in a Male Infant From Mexico
por: Cruz, Alonso
Publicado: (2012)

Genetic characterization and mutation analysis of Qihe547 Aujeszky’s disease virus in China
por: Liu, Cun, et al.
Publicado: (2018)

547 Volume-based Feeds: A Quality Improvement Project for Better Nutrition
por: Levine, Emma, et al.
Publicado: (2023)

FRI547 Orbital Surgery In Moderate-To-Severe Graves´Ophthalmopathy: Institutional Experience
por: Delfino, Laura, et al.
Publicado: (2023)

PT547. 17alfa-estradiol prevents gamma-aminobutyric signaling dysfunction induced by repeated stress in the hippocampus associated with behavioral abnormalities via G-protein-coupled estrogen receptor in ovariectomized mice
por: Tsukahara, Takao, et al.
Publicado: (2016)

Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database
por: Gartland, Margaret, et al.
Publicado: (2021)

Bright’s Disease
por: Clark, Alonzo
Publicado: (1882)

Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy
por: Muccini, Camilla, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iaeencfb0qsdcgrfa5e4q73dk3